For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Mannheim 68167
0 studies enrolling now · 15 studies all time
What they study most
Acute Coronary Syndrome, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Major Depressive Disorder, Metastatic Gastric Adenocarcinoma, Neoplasms, Hematologic, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Psoriasis
Studies at this site
- A Study of LY2784544 in Participants With Myeloproliferative Neoplasms — Running, not enrolling
- A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients — Completed
- A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer — Completed
- A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients — Completed
- A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) — Completed
- Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo — Stopped early
- Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease — Stopped early
- Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer — Completed
- A Study in the Treatment of Children and Adolescents With Major Depressive Disorder — Completed
- Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer — Completed
- Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo — Completed
- A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects — Completed
- Effect of LY2062430 on the Progression of Alzheimer's Disease — Completed
- Long-Term, Open Label Atomoxetine Study — Completed
- A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma — Withdrawn before enrolling